{'52WeekChange': 1.2168059,
 'SandP52WeekChange': 0.0644362,
 'address1': '200 Smith Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 47.78,
 'askSize': 800,
 'averageDailyVolume10Day': 328575,
 'averageVolume': 513623,
 'averageVolume10days': 328575,
 'beta': 2.167851,
 'beta3Year': None,
 'bid': 47.64,
 'bidSize': 900,
 'bookValue': 12.073,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 48.92,
 'dayLow': 46.85,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -8.922,
 'enterpriseToRevenue': 79.518,
 'enterpriseValue': 1992876288,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '785 830 2150',
 'fiftyDayAverage': 56.20257,
 'fiftyTwoWeekHigh': 71.11,
 'fiftyTwoWeekLow': 19.88,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 33954060,
 'forwardEps': -5.13,
 'forwardPE': -9.307992,
 'fromCurrency': None,
 'fullTimeEmployees': 255,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.30216,
 'heldPercentInstitutions': 0.67095,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/deciphera.com',
 'longBusinessSummary': 'Deciphera Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, develops drugs to enhance '
                        'the lives of cancer patients by addressing key '
                        'mechanisms of drug resistance that limit the rate and '
                        'durability of response of various cancer therapies. '
                        'Its lead drug candidate is ripretinib for the '
                        'treatment of gastrointestinal stromal tumors; and '
                        'that is in Phase I trial for treating gliomas, '
                        'melanoma, NSCLC/germ cell/penile, and soft tissue '
                        'sarcomas. The company is also developing immunokinase '
                        'inhibitors comprising DCC-3014 that is in Phase I '
                        'trial for the treatment of tenosynovial giant cell '
                        'tumors; and Rebastinib, which is in Phase Ib/II trial '
                        'to treat solid tumors, as well as to investigate in '
                        'combination with chemotherapy for the treatment of '
                        'multiple solid tumors. In addition, its preclinical '
                        'stage drug candidate is DCC-3116 for the treatment of '
                        'RAS mutant cancers. Deciphera has partnership with '
                        'K2fly, which offers cloud monitoring platform, to '
                        'create an integrated monitoring and governance '
                        'platform for tailing storage facilities. The company '
                        'was founded in 2003 and is headquartered in Waltham, '
                        'Massachusetts.',
 'longName': 'Deciphera Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 2662988800,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_8221694',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -217679008,
 'nextFiscalYearEnd': 1640908800,
 'open': 48.16,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.42,
 'phone': '781 209 6400',
 'previousClose': 48.86,
 'priceHint': 2,
 'priceToBook': 3.9551065,
 'priceToSalesTrailing12Months': 106.256035,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 48.92,
 'regularMarketDayLow': 46.85,
 'regularMarketOpen': 48.16,
 'regularMarketPreviousClose': 48.86,
 'regularMarketPrice': 48.16,
 'regularMarketVolume': 291421,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 55769400,
 'sharesPercentSharesOut': 0.0789,
 'sharesShort': 4404931,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3144901,
 'shortName': 'Deciphera Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1125,
 'shortRatio': 7.27,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'DCPH',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.657,
 'twoHundredDayAverage': 54.26694,
 'volume': 291421,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.deciphera.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}